WOW! Huge NEWS! $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G $IPIX
Protocol name
Double-blind, placebo-controlled, randomized, multicenter Phase II study to evaluate the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Therapeutic area
Anesthesiology and resuscitation, Infectious diseases, Oncology, Therapy (general), Surgery, Cardiology, Pulmonology, Toxicology
CI start and end date
12/17/2020 - 03/31/2021
RCT number and date
No. 705 dated 12/17/2020
CI organization
Innovation Pharmaceuticals Inc. (Innovation Pharmaceuticals Inc.)
Drug name
Brilacidin
Dosage form and dosage
solution for intravenous administration, 50 mg / ml
Cities
Barnaul, Kirovsk, Moscow, Nizhny Novgorod, Ryazan, St. Petersburg, Saratov, Yaroslavl
Developer country
USA
Organization involved by the drug developer
IPharma LLC, 143026, Moscow, the territory of the Skolkovo innovation center, st. Nobel, 7, Russia
CI phase
II
KI type
IMCI
The purpose of CI
assessment of the efficacy and safety of Brilacidin in patients hospitalized with COVID-19
Number of medical institutions
20
Number of patients
106
Where the research is done
one
KGBUZ "City Hospital No. 5, g. Barnaul "
Region
Altai region
Town
Barnaul
Researchers
Martynenko T.I.
2
GBUZ LO "Kirovskaya MB"
Region
Leningradskaya
Town
Kirovsk
Researchers
Klinov A.S
3
IKB No. 1
Region
Moscow city
Town
Moscow
Researchers
Nurmukhametova E.A.
four
GBUZ "GKB No. 52 DZM"
Region
Moscow city
Town
Moscow
Researchers
Fomina D.S
five
FSBI "Central Clinical Hospital with a Polyclinic"
Region
Moscow city
Town
Moscow
Researchers
Lomakin N.V.
6
GUZ GKB No. 15
Region
Moscow city
Town
Moscow
Researchers
Gordeev I.G.
7
FSBEI HE MGMSU them. A.I. Evdokimova, Ministry of Health of Russia
Region
Moscow city
Town
Moscow
Researchers
Vertkin A.L. , Rogova I.V.
8
GBUZ "NII SP named after N.V. Sklifosovsky Research Institute for Emergency Medicine "
Region
Moscow city
Town
Moscow
Researchers
Zhuravel S.V
9
FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University)
Region
Moscow city
Town
Moscow
Researchers
Moiseev S.V. , Smolyarchuk E.A.
ten
GUZ NO GKB No. 3 (NGTs)
Region
Nizhny Novgorod Region
Town
Nizhny Novgorod
Researchers
Makarova A.E
eleven
GBU RO "OKB"
Region
Ryazan Oblast
Town
Ryazan
Researchers
Ivanova A.Yu
12
SPb GBUZ "Nikolaevskaya hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Nigrieva Y.N
thirteen
SPb GBUZ "City Mariinsky Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Mamonov A.G.
14
S-Pb GUZ "City Hospital No. 38 named after N. A. Semashko"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Popov A.V
15
SPb GBUZ "City Hospital No. 15"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Goloshchekin B.M
16
SPb GBUZ "City Pokrovskaya Hospital"
Region
St. Petersburg
Town
St. Petersburg
Researchers
Khmelnitsky O.K
17
FGBOU VO Saratov State Medical University named after IN AND. Razumovsky Ministry of Health of Russia
Region
Saratov region
Town
Saratov
Researchers
Schwartz Yu.G
